Additional research has shown that GLP-1 RAs can inhibit prostate cancer growth by targeting the PI3K/AKT/mTOR and ERK/MAPK pathways and can also suppress pancreatic and prostate cancer cell growth by inhibiting the NF-kB pathway. Here, MTOR is linked to prostate carcinoma.